Table 1

Current landscape of systemic therapies for hepatocellular carcinoma

Treatment lineTreatmentPharmacological targetsClinical trial and IDResults
First-lineSorafenib
(vs. placebo)
Multiple kinases: VEGFR, PDGFR, etc.SHARP107
(NCT00105443)
2008/7
OS: 10.7 vs. 7.9 mo (HR 0.69, 95% CI 0.55–0.87, P < 0.001); TTP: 5.5 vs. 2.8 mo (P < 0.001)
Lenvatinib
(vs. sorafenib)
Multiple kinases: VEGFR, FGFR, etc.REFLECT108
(NCT01761266)
2018/3
OS 13.6 vs. 12.3 mo (HR 0.92, 95% CI 0.79–1.06); PFS 7.4 vs. 3.7 mo (HR 0.66, P < 0.001); ORR 24% vs. 9% (P < 0.001)
Atezolizumab + bevacizumab
(vs. sorafenib)
PD-L1 + VEGFIMbrave15041
(NCT03434379)
2020/3
OS: HR 0.58 (0.42–0.79, P < 0.001); PFS: 6.8 vs. 4.3 mo (HR 0.59, P < 0.001); ORR: 27.3% vs. 11.9% (CR 5.5% vs. 0%)
Tremelimumab + durvalumab
(vs. sorafenib)
CTLA-4 + PD-L1HIMALAYA109
(NCT03298451)
2022/8
OS 16.4 vs. 13.8 mo (HR 0.78, P = 0.0035); ORR 20.1% vs. 5.1% (CR 3.1% vs. 0%)
Camrelizumab + rivoceranib
(vs. sorafenib)
PD-1 + VEGFR2CARES-310110
(NCT03764293)
2023/8
OS: 22.1 vs. 15.2 mo (HR 0.62, 95% CI 0.49–0.80, P < 0.0001); PFS: 5.6 vs. 3.7 mo (HR 0.52, 95% CI 0.41–0.65, P < 0.0001); ORR: 25.4% vs. 5.9%
Tislelizumab
(vs. sorafenib)
PD-1RATIONALE-301111
(NCT03412773)
2023/12
OS: 15.9 vs. 14.1 mo (HR 0.85, 95% CI 0.71–1.02); PFS: 2.1 vs. 3.4 mo (HR 1.11, 95% CI 0.92–1.33); ORR: 14.3% vs. 5.4% (95% CI 1.57–4.85, P < 0.001)
Nivolumab + ipilimumab
(vs. lenvatinib
/sorafenib)
PD-1 + CTLA-4CheckMate-9 DW112
(NCT04039607)
2025/5
OS 23.7 vs. 20.6 mo (HR 0.79, 95% CI 0.65–0.96, P = 0.018); ORR 36% vs. 13% (P < 0.0001)
Second-lineRamucirumab
(vs. placebo)
VEGFR2REACH113
(NCT01140347)
2015/7
OS: 9.2 vs. 7.6 mo (HR 0.87, 95% CI 0.72–1.05, P = 0.14); PFS: 2.8 vs. 2.1 mo (HR 0.63, 95% CI 0.52–0.75, P < 0.0001); ORR: 7% vs. <1% (P < 0.0001)
Regorafenib
(vs. placebo)
Multiple kinases: KIT, RET, etc.RESORCE114
(NCT01774344)
2017/1
OS: 10.6 vs. 7.8 mo (HR 0.63, 95% CI 0.50–0.79, P < 0.0001); PFS: 3.1 vs. 1.5 mo (HR 0.46, 95% CI 0.37–0.56); ORR: 11% vs. 4% (P = 0.0047); TTP: 3.2 vs. 1.5 mo (HR 0.44)
Cabozantinib
(vs. placebo)
Multiple kinases: VEGFR, MET, etc.CELESTIAL115
(NCT01908426)
2018/7
OS: 10.2 vs. 8.0 mo (HR 0.76, 95% CI 0.63–0.92, P = 0.005); PFS: 5.2 vs. 1.9 mo (HR 0.44, 95% CI 0.36–0.52, P < 0.001); ORR: 4% vs. <1% (P = 0.009)
NivolumabPD-1CheckMate 040116
(NCT01658878)
2017/6
OS: 13.2 mo in sorafenib progressor cohort; ORR: 20% (sorafenib progressors 21%)
PembrolizumabPD-1KEYNOTE-394117
(NCT03062358)
2023/3
OS: 14.6 vs. 13.0 mo (HR 0.79, 95% CI 0.63–0.99, P = 0.018); PFS: 2.6 vs. 2.3 mo (HR 0.74, 95% CI 0.60–0.92, P = 0.0032); ORR: 12.7% vs. 1.3% (P < 0.0001)

CI, confidence interval; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; FGFR, fibroblast growth factor receptor; HR, hazard ratio; KIT, KIT proto-oncogene receptor tyrosine kinase; MET, MET proto-oncogene receptor tyrosine kinase; ORR, objective response rate; OS, median overall survival; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PDGFR, platelet-derived growth factor receptor; PFS, progression-free survival; RET, rearranged during transfection; TTP, time to progression; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.